Advanced Magnetics to continue ferumoxytol phase 3 studies

By Elaine Rigoli

Tampa, Fla., June 14 - Advanced Magnetics, Inc. said the independent Data Monitoring Committee providing oversight for the ferumoxytol phase 3 iron-replacement therapy program recommended the continuation of the studies with no modifications after a review of cumulative program safety data.

The committee said no safety concerns were identified for ferumoxytol in phase 3 multi-center clinical trials for use as an intravenous iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis.

Advanced Magnetics, located in Cambridge, Mass., is a developer of superparamagnetic iron oxide nanoparticles used in pharmaceutical products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.